Please check your internet connection and try again.
Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis
* Healing of duodenal ulcers
* Eradication of *Helicobacter pylori* infection (in combination with antibiotics)
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Higher doses (e.g., 40 mg twice daily) may be used for severe erosive esophagitis.
* **Duodenal Ulcers:** 40 mg orally once daily.
* ***H. pylori* Eradication (Triple Therapy):** 40 mg orally twice daily in combination with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily for 7-14 days.
* ***H. pylori* Eradication (Clarithromycin-Doxycycline-Based Quadruple Therapy):** 40 mg orally once daily in combination with bismuth subcitrate potassium 420 mg four times daily, doxycycline 100 mg twice daily, and metronidazole 500 mg four times daily for 10-14 days.
* **Pathological Hypersecretory Conditions:** Start at 40 mg orally or intravenously once daily. Titrate as needed. Doses may exceed 40 mg twice daily. Max dose usually 240 mg daily, divided.
## Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **12 years and older:** 40 mg orally once daily.
* **5-11 years:** 20 mg orally once daily.
* **Very limited data exists for children younger than 5 years.** Dosing in this population should be based on clinical judgment and potential risks and benefits.
## Dose Adjustments
No dose adjustment is typically required for renal impairment.
For severe hepatic impairment, a dose of 20 mg orally once daily is recommended.
## Contraindications
* Known hypersensitivity to pantoprazole or other substituted benzimidazoles.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
* **Serious:**
* *Clostridium difficile*-associated diarrhea (CDAD)
* Bone fracture (hip, wrist, spine) with long-term, high-dose use
* Hypomagnesemia (can be asymptomatic or manifest as tetany, arrhythmias, seizures)
* Vitamin B12 deficiency with long-term use
* Cutaneous and systemic lupus erythematosus
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** May decrease absorption of drugs such as ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Potential for interaction, though generally considered less significant than with omeprazole.
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile* infection.
* Monitor electrolytes (especially magnesium) with long-term therapy, particularly in patients at risk.
* Consider monitoring vitamin B12 levels with prolonged therapy.
* Monitor bone mineral density in patients at risk for osteoporosis.
## Clinical Pearls
* Pantoprazole is generally considered to have fewer CYP2C19 interactions than omeprazole.
* Oral administration can be with or without food.
* Do not crush or chew delayed-release formulations; swallow whole.
* IV administration is an option for patients unable to take oral medications.
* Long-term PPI use is associated with potential risks, and therapy should be periodically reassessed.
***
**Disclaimer:** This information is intended for clinical pharmacy professionals. It is essential to consult the most current prescribing information and institutional protocols for definitive guidance. Dosing may vary based on patient-specific factors and local guidelines.
